Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer

M. Gershanovich, H. A. Chaudri, D. Campos, H. Lurie, A. Bonaventura, M. Jeffrey, F. Buzzi, I. Bodrogi, H. Ludwig, P. Reichardt, N. O'Higgins, G. Romieu, P. Friederich, M. Lassus

Research output: Contribution to journalArticle

268 Citations (Scopus)

Abstract

Background: The study compares letrozole and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with antioestrogens. Patients and methods: 555 women were randomly assigned letrozole 2.5 mg once daily (n = 185), letrozole 0.5 mg once daily (n = 192) or aminoglutethimide 250 mg twice daily with corticosteroid support (n = 178) in an open-label, multicentre trial. The primary endpoint was objective response rate (ORR), with time events as secondary. ORR was analysed nine months after enrolment of the last patient, while survival was analysed 15 months after the last patient was enrolled. We report the results of these analyses plus an extended period of observation (covering a total duration of approximately 45 months) to determine the duration of response and clinical benefit. Results: Overall objective response rates (complete + partial) of 19.5%, 16.7%, and 12.4% were seen for letrozole 2.5 mg, 0.5 mg and AG respectively. Median duration of response and stable disease was longest for letrozole 2.5 mg (21 months) compared with letrozole 0.5 mg (18 months) and AG (14 months). Letrozole 2.5 mg was superior to AG in time to progression, time to treatment failure and overall survival. Treatment-related adverse events occurred in fewer patients on letrozole (33%) than on AG (46%). Transient nausea was the most frequent event with letrozole (7% on 0.5 mg, 10% on 2.5 mg, 10%, on AG), rash with AG (11%, 1% on 0.5 mg, 3% on 2.5 mg letrozole). Conclusions: Letrozole 2.5 mg offers longer disease control than aminoglutethimide and letrozole 0.5 mg in the treatment of postmenopausal women with advanced breast cancer, previously treated with anti-oestrogens.

Original languageEnglish
Pages (from-to)639-645
Number of pages7
JournalAnnals of Oncology
Volume9
Issue number6
DOIs
Publication statusPublished - Jun 1998

Fingerprint

letrozole
Aminoglutethimide
Aromatase Inhibitors
Breast Neoplasms

Keywords

  • Advanced breast cancer
  • Aminoglutethimide
  • Aromatase inhibitors
  • Letrozole

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Letrozole, a new oral aromatase inhibitor : Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. / Gershanovich, M.; Chaudri, H. A.; Campos, D.; Lurie, H.; Bonaventura, A.; Jeffrey, M.; Buzzi, F.; Bodrogi, I.; Ludwig, H.; Reichardt, P.; O'Higgins, N.; Romieu, G.; Friederich, P.; Lassus, M.

In: Annals of Oncology, Vol. 9, No. 6, 06.1998, p. 639-645.

Research output: Contribution to journalArticle

Gershanovich, M, Chaudri, HA, Campos, D, Lurie, H, Bonaventura, A, Jeffrey, M, Buzzi, F, Bodrogi, I, Ludwig, H, Reichardt, P, O'Higgins, N, Romieu, G, Friederich, P & Lassus, M 1998, 'Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer', Annals of Oncology, vol. 9, no. 6, pp. 639-645. https://doi.org/10.1023/A:1008226721932
Gershanovich, M. ; Chaudri, H. A. ; Campos, D. ; Lurie, H. ; Bonaventura, A. ; Jeffrey, M. ; Buzzi, F. ; Bodrogi, I. ; Ludwig, H. ; Reichardt, P. ; O'Higgins, N. ; Romieu, G. ; Friederich, P. ; Lassus, M. / Letrozole, a new oral aromatase inhibitor : Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. In: Annals of Oncology. 1998 ; Vol. 9, No. 6. pp. 639-645.
@article{0c82ed7b376b43ffb70b666ea6bce72b,
title = "Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer",
abstract = "Background: The study compares letrozole and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with antioestrogens. Patients and methods: 555 women were randomly assigned letrozole 2.5 mg once daily (n = 185), letrozole 0.5 mg once daily (n = 192) or aminoglutethimide 250 mg twice daily with corticosteroid support (n = 178) in an open-label, multicentre trial. The primary endpoint was objective response rate (ORR), with time events as secondary. ORR was analysed nine months after enrolment of the last patient, while survival was analysed 15 months after the last patient was enrolled. We report the results of these analyses plus an extended period of observation (covering a total duration of approximately 45 months) to determine the duration of response and clinical benefit. Results: Overall objective response rates (complete + partial) of 19.5{\%}, 16.7{\%}, and 12.4{\%} were seen for letrozole 2.5 mg, 0.5 mg and AG respectively. Median duration of response and stable disease was longest for letrozole 2.5 mg (21 months) compared with letrozole 0.5 mg (18 months) and AG (14 months). Letrozole 2.5 mg was superior to AG in time to progression, time to treatment failure and overall survival. Treatment-related adverse events occurred in fewer patients on letrozole (33{\%}) than on AG (46{\%}). Transient nausea was the most frequent event with letrozole (7{\%} on 0.5 mg, 10{\%} on 2.5 mg, 10{\%}, on AG), rash with AG (11{\%}, 1{\%} on 0.5 mg, 3{\%} on 2.5 mg letrozole). Conclusions: Letrozole 2.5 mg offers longer disease control than aminoglutethimide and letrozole 0.5 mg in the treatment of postmenopausal women with advanced breast cancer, previously treated with anti-oestrogens.",
keywords = "Advanced breast cancer, Aminoglutethimide, Aromatase inhibitors, Letrozole",
author = "M. Gershanovich and Chaudri, {H. A.} and D. Campos and H. Lurie and A. Bonaventura and M. Jeffrey and F. Buzzi and I. Bodrogi and H. Ludwig and P. Reichardt and N. O'Higgins and G. Romieu and P. Friederich and M. Lassus",
year = "1998",
month = "6",
doi = "10.1023/A:1008226721932",
language = "English",
volume = "9",
pages = "639--645",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Letrozole, a new oral aromatase inhibitor

T2 - Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer

AU - Gershanovich, M.

AU - Chaudri, H. A.

AU - Campos, D.

AU - Lurie, H.

AU - Bonaventura, A.

AU - Jeffrey, M.

AU - Buzzi, F.

AU - Bodrogi, I.

AU - Ludwig, H.

AU - Reichardt, P.

AU - O'Higgins, N.

AU - Romieu, G.

AU - Friederich, P.

AU - Lassus, M.

PY - 1998/6

Y1 - 1998/6

N2 - Background: The study compares letrozole and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with antioestrogens. Patients and methods: 555 women were randomly assigned letrozole 2.5 mg once daily (n = 185), letrozole 0.5 mg once daily (n = 192) or aminoglutethimide 250 mg twice daily with corticosteroid support (n = 178) in an open-label, multicentre trial. The primary endpoint was objective response rate (ORR), with time events as secondary. ORR was analysed nine months after enrolment of the last patient, while survival was analysed 15 months after the last patient was enrolled. We report the results of these analyses plus an extended period of observation (covering a total duration of approximately 45 months) to determine the duration of response and clinical benefit. Results: Overall objective response rates (complete + partial) of 19.5%, 16.7%, and 12.4% were seen for letrozole 2.5 mg, 0.5 mg and AG respectively. Median duration of response and stable disease was longest for letrozole 2.5 mg (21 months) compared with letrozole 0.5 mg (18 months) and AG (14 months). Letrozole 2.5 mg was superior to AG in time to progression, time to treatment failure and overall survival. Treatment-related adverse events occurred in fewer patients on letrozole (33%) than on AG (46%). Transient nausea was the most frequent event with letrozole (7% on 0.5 mg, 10% on 2.5 mg, 10%, on AG), rash with AG (11%, 1% on 0.5 mg, 3% on 2.5 mg letrozole). Conclusions: Letrozole 2.5 mg offers longer disease control than aminoglutethimide and letrozole 0.5 mg in the treatment of postmenopausal women with advanced breast cancer, previously treated with anti-oestrogens.

AB - Background: The study compares letrozole and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with antioestrogens. Patients and methods: 555 women were randomly assigned letrozole 2.5 mg once daily (n = 185), letrozole 0.5 mg once daily (n = 192) or aminoglutethimide 250 mg twice daily with corticosteroid support (n = 178) in an open-label, multicentre trial. The primary endpoint was objective response rate (ORR), with time events as secondary. ORR was analysed nine months after enrolment of the last patient, while survival was analysed 15 months after the last patient was enrolled. We report the results of these analyses plus an extended period of observation (covering a total duration of approximately 45 months) to determine the duration of response and clinical benefit. Results: Overall objective response rates (complete + partial) of 19.5%, 16.7%, and 12.4% were seen for letrozole 2.5 mg, 0.5 mg and AG respectively. Median duration of response and stable disease was longest for letrozole 2.5 mg (21 months) compared with letrozole 0.5 mg (18 months) and AG (14 months). Letrozole 2.5 mg was superior to AG in time to progression, time to treatment failure and overall survival. Treatment-related adverse events occurred in fewer patients on letrozole (33%) than on AG (46%). Transient nausea was the most frequent event with letrozole (7% on 0.5 mg, 10% on 2.5 mg, 10%, on AG), rash with AG (11%, 1% on 0.5 mg, 3% on 2.5 mg letrozole). Conclusions: Letrozole 2.5 mg offers longer disease control than aminoglutethimide and letrozole 0.5 mg in the treatment of postmenopausal women with advanced breast cancer, previously treated with anti-oestrogens.

KW - Advanced breast cancer

KW - Aminoglutethimide

KW - Aromatase inhibitors

KW - Letrozole

UR - http://www.scopus.com/inward/record.url?scp=7344242595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7344242595&partnerID=8YFLogxK

U2 - 10.1023/A:1008226721932

DO - 10.1023/A:1008226721932

M3 - Article

C2 - 9681078

AN - SCOPUS:7344242595

VL - 9

SP - 639

EP - 645

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -